Focus up with this drink made for gamers
Focus up with this drink made for gamers
MELBOURNE, Australia and INDIANAPOLIS, Jan. 24, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that the first patients have been dosed in the Phase III ZIRCON1 clinical trial of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in the United States. The objective of the ZIRCON trial is to evaluate the sensitivity and specificity of PET/CT imaging with TLX250-CDx to non-invasively detect clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses in comparison with surgical resection (histology), as the standard of truth. The ZIRCON trial, which includes twelve participating clinical study sites across the U.S. and Canada, initiated patient recruitment in U.S. on Friday, with the first patients being dosed with TLX250-CDx at University of California, Los Angeles (UCLA), and Seattle Cancer Care Alliance, University of Washington, Seattle (SCCA). The remaining seven U.S. sites2 and three sites3 in Canada are expected to commence patient recruitment progressively over the next month. Telix Chief Medical Officer, Dr. Colin Hayward, stated, “We are pleased to have commenced the Phase III ZIRCON clinical trial in North America and wish to express our gratitude to Prof. Allan Pantuck and Dr. Delphine Chen, principal investigators at UCLA and SCCA, respectively, as well as their clinical research teams and patients, who have made this important milestone possible.” About the ZIRCON Study ZIRCON (“Zirconium Imaging in Renal Cancer Oncology”) is an international multi-centre Phase III study at 36 sites in Europe, Australia, Turkey, Canada, and the United States (subject to regulatory approval in the various jurisdictions). ZIRCON is a prospective imaging trial in approximately 250 renal cancer patients undergoing kidney surgery, to determine the sensitivity and specificity of TLX250-CDx PET imaging to detect clear cell renal cell cancer (ccRCC) in comparison with histologic “ground truth” determined from surgical resection specimens. About TLX250-CDx TLX250-CDx (89Zr-girentuximab) is being developed by Telix for the purpose of determining whether “indeterminate renal masses”, typically identified based on CT or MRI imaging, are either clear cell renal cell cancer (ccRCC) or non-ccRCC, using Positron Emission Tomography (PET) imaging. Girentuximab is a monoclonal antibody that targets carbonic anhydrase IX (CAIX), a cell surface target that is highly expressed in several human cancers including renal, lung and oesophageal cancers. In July 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy (BT) designation for TLX250-CDx, reflecting the significant unmet clinical need to improve the diagnosis and staging of ccRCC, the most common and aggressive form of kidney cancer. About Telix Pharmaceuticals Limited Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information, please follow Telix on Twitter @TelixPharma and LinkedIn, and visit www.telixpharma.com. Telix’s lead product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA4, and has been granted Priority Review status by the Therapeutic Goods Administration (TGA) in Australia.5 Telix is also progressing marketing authorisation applications for Illuccix® in the European Union6 and Canada.7 None of Telix’s products have currently received a marketing authorisation in any jurisdiction. Telix Corporate Contact Telix Investor RelationsDr. Christian BehrenbruchDr. David N. CadeTelix Pharmaceuticals LimitedTelix Pharmaceuticals LimitedCEO CBO and Head of Investor RelationsEmail: Christian@telixpharma.comEmail: email@example.com 1 ClinicalTrials.Gov Identifier: NCT03849118.2 City of Hope, Duarte California; Advanced Molecular Imaging and Therapy, Maryland; Barbara Ann Karmanos Cancer Hospital, Detroit; Emory University, Atlanta Georgia; John Hopkins, Baltimore; Washington University, St Louis; Memorial Sloan Kettering, New York City.3 Sir Mortimer B. Davis Jewish General Hospital, Montreal; CHU de Québec-Université Laval, Quebec City; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal.4 ASX release 24th November 2020.5 ASX release 7th December 2020.6 ASX release 1st May 2020.7 ASX release 16th December 2020.
The night was also one for the record books as Thierry Small became the youngest player in the club’s history.
Time flies! Adele is surprised to see her record-breaking "21" celebrates its 10th anniversary on Sunday.
Follow for the latest developments
The stock market is riding a bullish wave, but here comes a tsunami of earnings, led by Apple and Tesla. With the Nasdaq extended, here's what to do.
Jessica Korda closed with a 5-under 66 and holed a 30-foot birdie putt on the first playoff hole Sunday to beat Danielle Kang in the Diamond Resorts Tournament of Champions and start the LPGA Tour season on a good note. Korda won for the sixth time on the LPGA Tour, and it was her first victory in nearly three years. Kang started the final round at Four Seasons Golf and Sports Club Orlando with a two-shot lead, which she quickly stretched to four shots with an opening birdie and Korda dropping a shot on the third hole.
Tatum won't be suiting up to play the Cavs, but is anticipated to return to action Monday against the Bulls.
Uros Racic fired the visitors in front just 11 minutes.
"Keep making me proud," Abby Lee Miller said
The WNBA's orange hoodie campaign took off after Kobe Bryant's death one year ago. It's now part of his legacy.
First family orders sesame bagels with cream cheese
Wayne Simmonds (Toronto Maple Leafs) with a Goal vs. Calgary Flames, 01/24/2021
"I don't want to die. An op is the only way I can lose weight."
The new Adidas shoes are designed in Oklahoma City Thunder colors and have Damian Lillard's stats from the epic 2019 game on them.
Atletico Madrid hasn't flinched in its quest to win the Spanish league title for the first time since 2014. Coming from behind for a second straight time, Atletico defeated Valencia 3-1 on Sunday to strengthen its hold on the league lead entering the second half of the season. Barcelona earlier picked up its second win in a row without the suspended Lionel Messi, defeating Elche 2-0 to regain third place.
Just after it became official, Gerrit Cole started spreading the news on Instagram. The Yankees’ ace was being reunited with his former spring training roommate. The Bombers had completed a trade for right-hander Jameson Taillon for four prospects. It’s a chance for Cole and Taillon to reach heights they trained to attain when they were the cornerstone of Pirates hopes back in their younger ...
Stussy and Nike have joined forces again.
Mohamed Salah scored twice for the visitors in a pulsating encounter.
Recently Shawn Davis with AutotopiaLA got to meet up with Nick at Dean’s SoCal Classic Car Storage to discuss his absolutely radical 63-½ Galaxie 500 Fastback build.
President Joe Biden on Monday will formally reinstate COVID-19 travel restrictions on non-U.S. travelers from Brazil, Ireland, the United Kingdom and 26 other European countries that allow travel across open borders, according to two White House officials. The officials, who spoke on the condition of anonymity to discuss the order, also confirmed Sunday that South Africa would be added to the restricted list because of concerns about a variant of the virus that has spread beyond that nation. Biden is reversing an order from President Donald Trump in his final days in office that called for the relaxation of the travel restrictions as of Tuesday.